Novartis Confident Cosentyx Can Keep Competition At Bay
Sales Expected To Grow Beyond $5bn
The Swiss major's biggest seller rose 12% in the second quarter and while COVID-19 had an impact, and competition is on the rise, Cosentyx is still outpacing the market overall in psoriasis, while rheumatology should drive future growth.
